Sino Biopharmaceutical Limited (SBHMY)
USD 8.34
(0.0%)
USD 8.34
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 21.2 Billion CNY | -7.72% |
| 2022 | 22.98 Billion CNY | 6.76% |
| 2021 | 21.52 Billion CNY | 16.6% |
| 2020 | 18.46 Billion CNY | -4.37% |
| 2019 | 19.3 Billion CNY | 15.67% |
| 2018 | 16.69 Billion CNY | 42.31% |
| 2017 | 11.72 Billion CNY | 4.5% |
| 2016 | 11.22 Billion CNY | 18.6% |
| 2015 | 9.46 Billion CNY | 25.12% |
| 2014 | 7.56 Billion CNY | 26.14% |
| 2013 | 5.99 Billion CNY | 12.74% |
| 2012 | 5.31 Billion CNY | 44.75% |
| 2011 | 3.67 Billion CNY | 30.58% |
| 2010 | 2.81 Billion CNY | 22.71% |
| 2009 | 2.29 Billion CNY | 43.94% |
| 2008 | 1.59 Billion CNY | 77.39% |
| 2007 | 897.92 Million CNY | 50.29% |
| 2006 | 597.47 Million CNY | -6.92% |
| 2005 | 641.89 Million CNY | -30.27% |
| 2004 | 920.57 Million CNY | 32.22% |
| 2003 | 696.24 Million CNY | 19.93% |
| 2002 | 580.53 Million CNY | 24.76% |
| 2001 | 465.33 Million CNY | 41.6% |
| 2000 | 328.62 Million CNY | 38.05% |
| 1999 | 238.05 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.8 Billion USD | 0.0% |
| 2023 Q1 | 6.01 Billion USD | 290.38% |
| 2023 FY | 21.2 Billion CNY | -7.72% |
| 2023 Q3 | - USD | -100.0% |
| 2023 Q4 | 1.26 Billion USD | 0.0% |
| 2023 Q2 | 1.73 Billion USD | -71.14% |
| 2022 Q4 | 1.53 Billion USD | -71.36% |
| 2022 Q1 | 6.11 Billion CNY | 23.22% |
| 2022 Q2 | 6.11 Billion CNY | 0.0% |
| 2022 FY | 22.98 Billion CNY | 6.76% |
| 2022 Q3 | 5.37 Billion USD | -12.12% |
| 2021 Q2 | 5.77 Billion CNY | -0.93% |
| 2021 Q4 | 4.96 Billion CNY | 0.0% |
| 2021 Q3 | 4.96 Billion CNY | -14.01% |
| 2021 FY | 21.52 Billion CNY | 16.6% |
| 2021 Q1 | 5.82 Billion CNY | 32.03% |
| 2020 Q3 | 4.19 Billion CNY | -14.39% |
| 2020 FY | 18.46 Billion CNY | -4.37% |
| 2020 Q1 | 4.95 Billion CNY | 31.85% |
| 2020 Q2 | 4.9 Billion CNY | -1.1% |
| 2020 Q4 | 4.41 Billion CNY | 5.2% |
| 2019 Q1 | 4.99 Billion CNY | 23.38% |
| 2019 FY | 19.3 Billion CNY | 15.67% |
| 2019 Q4 | 3.75 Billion CNY | -31.35% |
| 2019 Q3 | 5.47 Billion CNY | 7.76% |
| 2019 Q2 | 5.08 Billion CNY | 1.7% |
| 2018 FY | 16.69 Billion CNY | 42.31% |
| 2018 Q1 | 3.71 Billion CNY | 38.49% |
| 2018 Q2 | 4.15 Billion CNY | 12.02% |
| 2018 Q3 | 4.77 Billion CNY | 14.92% |
| 2018 Q4 | 4.04 Billion CNY | -15.24% |
| 2017 Q4 | 2.67 Billion CNY | -14.54% |
| 2017 Q3 | 3.13 Billion CNY | 9.6% |
| 2017 Q2 | 2.86 Billion CNY | -6.35% |
| 2017 Q1 | 3.05 Billion CNY | 8.03% |
| 2017 FY | 11.72 Billion CNY | 4.5% |
| 2016 Q3 | 2.97 Billion CNY | 11.59% |
| 2016 Q1 | 2.74 Billion CNY | 25.05% |
| 2016 Q4 | 2.82 Billion CNY | -5.06% |
| 2016 FY | 11.22 Billion CNY | 18.6% |
| 2016 Q2 | 2.66 Billion CNY | -2.93% |
| 2015 Q2 | 2.25 Billion CNY | -3.56% |
| 2015 FY | 9.46 Billion CNY | 25.12% |
| 2015 Q1 | 2.34 Billion CNY | 23.21% |
| 2015 Q4 | 2.19 Billion CNY | -17.54% |
| 2015 Q3 | 2.66 Billion CNY | 18.12% |
| 2014 Q4 | 1.89 Billion CNY | -2.81% |
| 2014 Q2 | 1.87 Billion CNY | 2.64% |
| 2014 Q1 | 1.83 Billion CNY | 30.77% |
| 2014 FY | 7.56 Billion CNY | 26.14% |
| 2014 Q3 | 1.95 Billion CNY | 4.04% |
| 2013 Q1 | 1.47 Billion CNY | 7.47% |
| 2013 Q2 | 1.49 Billion CNY | 1.36% |
| 2013 Q3 | 1.63 Billion CNY | 9.25% |
| 2013 Q4 | 1.39 Billion CNY | -14.17% |
| 2013 FY | 5.99 Billion CNY | 12.74% |
| 2012 Q1 | 1.14 Billion CNY | 24.17% |
| 2012 Q4 | 1.37 Billion CNY | -1.83% |
| 2012 Q3 | 1.39 Billion CNY | -0.8% |
| 2012 Q2 | 1.4 Billion CNY | 22.92% |
| 2012 FY | 5.31 Billion CNY | 44.75% |
| 2011 Q2 | 923.8 Million CNY | 14.33% |
| 2011 Q1 | 807.99 Million CNY | 0.0% |
| 2011 FY | 3.67 Billion CNY | 30.58% |
| 2011 Q3 | 1.02 Billion CNY | 10.43% |
| 2011 Q4 | 921.93 Million CNY | -9.63% |
| 2010 Q2 | 711.13 Million CNY | 13.3% |
| 2010 Q1 | 627.65 Million CNY | 0.0% |
| 2010 FY | 2.81 Billion CNY | 22.71% |
| 2009 FY | 2.29 Billion CNY | 43.94% |
| 2008 FY | 1.59 Billion CNY | 77.39% |
| 2007 FY | 897.92 Million CNY | 50.29% |
| 2006 FY | 597.47 Million CNY | -6.92% |
| 2005 FY | 641.89 Million CNY | -30.27% |
| 2004 FY | 920.57 Million CNY | 32.22% |
| 2003 FY | 696.24 Million CNY | 19.93% |
| 2002 FY | 580.53 Million CNY | 24.76% |
| 2001 FY | 465.33 Million CNY | 41.6% |
| 2000 FY | 328.62 Million CNY | 38.05% |
| 1999 FY | 238.05 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -141306.307% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -683737230.754% |
| SQZ Biotechnologies Company | 9.79 Million USD | -216456.381% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -181085.136% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -17707.039% |
| Mesoblast Limited | -35.16 Million USD | 60409.179% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 62107075.11% |
| Genus plc | 178.7 Million USD | -11768.792% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -5170875.583% |
| Marizyme, Inc. | 457.7 Thousand USD | -4633817.265% |
| ContraFect Corporation | -154 Thousand USD | 13772523.377% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 192814027.273% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 42419164.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -27630509.294% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -32268540.458% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 5473513.488% |
| MultiCell Technologies, Inc. | 49.32 USD | -43003917174.939% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -52574.859% |
| EV Biologics, Inc. | 48.9 Thousand USD | -43373176.074% |
| Q BioMed Inc. | -8988.00 USD | 235976201.469% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -74964.704% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 137510032.573% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | -9536.141% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -30299231.429% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 17070008.492% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -34084578.43% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 428302442.488% |
| Arch Therapeutics, Inc. | -2439.00 USD | 869599607.995% |
| IMV Inc. | -962.29 Thousand USD | 2204150.305% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -15095652.313% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 21750119.997% |
| GB Sciences, Inc. | -624.00 USD | 3398963561.538% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 24654319.556% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | -180.512% |
| Halberd Corporation | -208.00 USD | 10196890484.615% |
| Enzolytics Inc. | 30.7 Thousand USD | -69068325.166% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -1562707.457% |
| SYBLEU INC | 11.69 Thousand USD | -181339947.88% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -4396268.408% |
| argenx SE | 1.1 Billion USD | -1813.387% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 82313.862% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -3435287.376% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | -5078.703% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 239493460.434% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -47714.647% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 1858023.285% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -2146655.049% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -220579.763% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 25295013.475% |
| BioStem Technologies, Inc. | 15.42 Million USD | -137402.382% |
| ONE Bio Corp. | 20.12 Million USD | -105286.67% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 179210340.811% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 43949481.463% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -12012548.391% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -12012548.391% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 4122377.895% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 3365955.098% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 73136417.241% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -4712679.001% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 6638305.736% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -460176.302% |
| Bioxytran, Inc. | -8285.00 USD | 255999279.24% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 5686301.609% |
| Neutra Corp. | 14.33 Thousand USD | -147956174.852% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 25865382.927% |
| PureTech Health plc | -1.6 Million USD | 1323214.91% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 2118434.938% |
| IXICO plc | 3.27 Million USD | -648509.541% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 3056228.53% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 1184328.476% |
| CSL Limited | 7.7 Billion USD | -175.27% |
| Cellectis S.A. | 18 Thousand USD | -117830633.333% |